Background
Results
BRCA1-mutated breast cancer displayed a hypermethylated E2F1 motif and promoter region
Low DNMT1 transcript levels showed a significant inverse correlation with hypermethylated E2F1 motif in BRCA1-mutated breast cancer
Hypermethylated E2F1 motif is a key regulatory mechanism for DNMT1 transcription in BRCA1-mutated breast cancer
Loss of H3K9ac and E2F1 enrichment around the hypermethylated E2F1 motif in BRCA1-mutated breast cancer
H3K9ac and E2F1 present in the E2F1 motif are responsible for the transcriptional regulation of DNMT1 in BRCA1-mutated breast cancer
Correlation of E2F1 motif methylation with clinicopathological characteristics in BRCA1-mutated breast cancer
n
| M | (%) | UM | (%) |
P
| |
---|---|---|---|---|---|---|
Age at diagnosis
|
1.000
| |||||
≤ 50 y | 30 | 14 | 35.90 | 16 | 34.78 | |
> 50 y | 55 | 25 | 64.10 | 30 | 65.22 | |
Menstrual status
|
0.282
| |||||
Premenopausal | 38 | 20 | 51.28 | 18 | 39.13 | |
Postmenopausal | 47 | 19 | 48.72 | 28 | 60.87 | |
Tumor size
|
0.164
| |||||
≤ 5 cm | 59 | 24 | 61.54 | 35 | 76.09 | |
> 5 cm | 26 | 15 | 38.46 | 11 | 23.91 | |
Histological grade
|
0.006
| |||||
I-II | 63 | 23 | 58.97 | 40 | 86.96 | |
III | 22 | 16 | 41.03 | 6 | 13.04 | |
LN status
|
0.014
| |||||
Positive | 35 | 22 | 56.41 | 13 | 28.26 | |
Negative | 50 | 17 | 43.59 | 33 | 71.74 | |
ER status
|
0.282
| |||||
Positive | 47 | 19 | 48.72 | 28 | 60.87 | |
Negative | 38 | 20 | 51.28 | 18 | 39.13 | |
PR status
|
0.269
| |||||
Positive | 50 | 20 | 51.28 | 30 | 65.22 | |
Negative | 35 | 19 | 48.72 | 16 | 34.78 | |
c-erbB-2 status
|
0.378
| |||||
Positive | 36 | 19 | 48.72 | 17 | 36.96 | |
Negative | 49 | 20 | 51.28 | 29 | 63.04 | |
p53 status
|
0.258
| |||||
Positive | 30 | 11 | 28.21 | 19 | 41.30 | |
Negative | 55 | 28 | 71.79 | 27 | 58.70 | |
Ki67 status
|
0.030
| |||||
Positive | 62 | 33 | 84.62 | 29 | 63.04 | |
Negative | 23 | 6 | 15.38 | 17 | 36.96 | |
E-cadherin status
|
0.030
| |||||
Positive | 68 | 27 | 69.23 | 41 | 89.13 | |
Negative | 17 | 12 | 30.77 | 5 | 10.87 |
Multivariate and univariate analysis of overall survival for patients with BRCA1-mutated breast cancer
Variable | RR | 95%CI |
P
|
---|---|---|---|
Age at diagnosis (> 50 y vs ≤ 50 y) | 1.059 | 0.982-1.143 | 0.137 |
Menstrual status (Post vs Pre) | 0.258 | 0.043-1.542 | 0.138 |
Tumor size (> 5 cm vs ≤ 5 cm) | 0.389 | 0.107-1.413 | 0.151 |
Histological grade (III vs I-II) | 2.628 | 0.642-10.761 | 0.179 |
LN status (Pos vs Neg) | 3.511 | 1.074-11.481 | 0.038 |
ER status (Pos vs Neg) | 0.561 | 0.123-2.554 | 0.455 |
PR status (Pos vs Neg) | 1.558 | 0.420-5.775 | 0.507 |
c-erbB-2 status (Pos vs Neg) | 1.429 | 0.422-4.832 | 0.566 |
p53 status (Pos vs Neg) | 0.437 | 0.112-1.703 | 0.233 |
Ki67 status (Pos vs Neg) | 0.628 | 0.120-3.271 | 0.580 |
E-cadherin status (Pos vs Neg) | 0.651 | 0.158-2.678 | 0.552 |
DNMT1 methylation (M vs UM) | 1.386 | 0.337-5.699 | 0.651 |